The Experts below are selected from a list of 501 Experts worldwide ranked by ideXlab platform

David P. Skoner - One of the best experts on this subject based on the ideXlab platform.

  • Modulation of Histamine Release by Sodium, Potassium Adenosine Triphosphatase Inhibition
    Annals of Allergy Asthma & Immunology, 1996
    Co-Authors: Deborah A. Gentile, E. R. Braun, David P. Skoner
    Abstract:

    Background Previous studies have shown that a sodium potassium Adenosine Triphosphatase Inhibitor is present in the plasma of allergic subjects in whom enhanced histamine releaseability has also been reported. Purpose The purpose of this study was to determine the effect of in vitro sodium, potassium Adenosine Triphosphatase inhibition on whole blood histamine release. Methods Samples obtained from 12 patients with allergic rhinitis and 12 nonallergic subjects were incubated in duplicate for 30 minutes with anti-IgE antibody (100 μg/mL) or control buffer following a 0-, 10-, 20-, 30-, 60-, 120- and 180-minute preincubation with ouabain (3.0 mM) or diluent. Cell supernatants were assayed for histamine by radioimmunoassay and results were expressed as a percentage of total histamine release. Results Mean (± 1 SEM) anti-IgE induced release, in the presence and absence of ouabain, respectively, for allergic subjects was 27.5 ± 5.5 and 21.0 ± 4.5 (10 minutes, P P P P P P P .005). Ouabain did not significantly alter histamine release in non-allergic subjects. Conclusions These days show that ouabian induced a significant increase in both spontaneous and induced histamine release in allergic subjects. In vivo, sodium, potassium Adenosine Triphosphatase inhibition may have an effect on histamine release in allergic subjects.

Deborah A. Gentile - One of the best experts on this subject based on the ideXlab platform.

  • Modulation of Histamine Release by Sodium, Potassium Adenosine Triphosphatase Inhibition
    Annals of Allergy Asthma & Immunology, 1996
    Co-Authors: Deborah A. Gentile, E. R. Braun, David P. Skoner
    Abstract:

    Background Previous studies have shown that a sodium potassium Adenosine Triphosphatase Inhibitor is present in the plasma of allergic subjects in whom enhanced histamine releaseability has also been reported. Purpose The purpose of this study was to determine the effect of in vitro sodium, potassium Adenosine Triphosphatase inhibition on whole blood histamine release. Methods Samples obtained from 12 patients with allergic rhinitis and 12 nonallergic subjects were incubated in duplicate for 30 minutes with anti-IgE antibody (100 μg/mL) or control buffer following a 0-, 10-, 20-, 30-, 60-, 120- and 180-minute preincubation with ouabain (3.0 mM) or diluent. Cell supernatants were assayed for histamine by radioimmunoassay and results were expressed as a percentage of total histamine release. Results Mean (± 1 SEM) anti-IgE induced release, in the presence and absence of ouabain, respectively, for allergic subjects was 27.5 ± 5.5 and 21.0 ± 4.5 (10 minutes, P P P P P P P .005). Ouabain did not significantly alter histamine release in non-allergic subjects. Conclusions These days show that ouabian induced a significant increase in both spontaneous and induced histamine release in allergic subjects. In vivo, sodium, potassium Adenosine Triphosphatase inhibition may have an effect on histamine release in allergic subjects.

E. R. Braun - One of the best experts on this subject based on the ideXlab platform.

  • Modulation of Histamine Release by Sodium, Potassium Adenosine Triphosphatase Inhibition
    Annals of Allergy Asthma & Immunology, 1996
    Co-Authors: Deborah A. Gentile, E. R. Braun, David P. Skoner
    Abstract:

    Background Previous studies have shown that a sodium potassium Adenosine Triphosphatase Inhibitor is present in the plasma of allergic subjects in whom enhanced histamine releaseability has also been reported. Purpose The purpose of this study was to determine the effect of in vitro sodium, potassium Adenosine Triphosphatase inhibition on whole blood histamine release. Methods Samples obtained from 12 patients with allergic rhinitis and 12 nonallergic subjects were incubated in duplicate for 30 minutes with anti-IgE antibody (100 μg/mL) or control buffer following a 0-, 10-, 20-, 30-, 60-, 120- and 180-minute preincubation with ouabain (3.0 mM) or diluent. Cell supernatants were assayed for histamine by radioimmunoassay and results were expressed as a percentage of total histamine release. Results Mean (± 1 SEM) anti-IgE induced release, in the presence and absence of ouabain, respectively, for allergic subjects was 27.5 ± 5.5 and 21.0 ± 4.5 (10 minutes, P P P P P P P .005). Ouabain did not significantly alter histamine release in non-allergic subjects. Conclusions These days show that ouabian induced a significant increase in both spontaneous and induced histamine release in allergic subjects. In vivo, sodium, potassium Adenosine Triphosphatase inhibition may have an effect on histamine release in allergic subjects.

Roland Valdes - One of the best experts on this subject based on the ideXlab platform.

  • secretion of a lactone hydrogenated ouabain like effector of sodium potassium Adenosine Triphosphatase activity by adrenal cells
    Endocrinology, 2000
    Co-Authors: Hassan M Qazzaz, Adnan M Elmasri, Roland Valdes
    Abstract:

    Ouabain-like factor (OLF), a mammalian cardenolide, is a counterpart to plant-derived ouabain and is found in the adrenal, hypothalamus, and blood of several mammalian species. We now report the existence of a mammalian lactone-hydrogenated ouabain-like factor (dihydro-OLF) in secretions from cultured mouse adrenal Y-1 cells. Dihydro-OLF structurally and functionally mimics plant-derived dihydroouabain. We measured both OLF and the newly discovered dihydro-OLF using five independent techniques: immunoreactivity with two specific antisera, one against ouabain and one against dihydroouabain; chromatographic mobility; spectral absorbance characteristics; and concentration-dependent inhibition and phosphorylation of Na,K-Adenosine Triphosphatase. All measured physical attributes of dihydro-OLF mimic those of plant-derived dihydroouabain, including a spectral shift maxima, 220 nm (OLF) to 196 nm (dihydro-OLF), with appropriately decreased molar absorptivity. Dihydro-OLF (IC50 = 590 nM) is a 10-fold less potent Na+,K+-Adenosine Triphosphatase Inhibitor than its oxidized mammalian counterpart OLF (IC50 = 60 nM), just as dihydroouabain is less potent than ouabain. Dihydro-OLF is also 3-fold more potent than a recently identified isomer of plant-derived dihydroouabain (IC50 = 1,700 nM). Using antiouabain and antidihydroouabain antisera we estimate that 3 x 10(7) mouse adrenal Y-1 cells secreted 1.3 ng OLF and 8.9 ng dihydro-OLF. The relative abundance of dihydro-OLF is consistently greater than that of its oxidized form, OLF, in bovine adrenals (22-fold), human serum (13-fold), and secretions from cultured mouse Y-1 cells (5-fold). The discoveries of OLF, OLF-genin, and now dihydro-OLF constitute an intriguing structural polymorphism probably involved in the synthesis, regulation, and metabolic control of these new hormone-like compounds.

Franklin W Smyth - One of the best experts on this subject based on the ideXlab platform.